drugset / Trial / NCT00222729
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Phase 2
Completed
42 enrolled
University of Pittsburgh
Eli Lilly and Company · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination of two new drugs pemetrexed (Alimta) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and neck cancer. Currently pemetrexed is approved by the Food and Drug Administration (FDA) for another type of cancer, mesothelioma, but it is not approved for head and neck cancer.
Timeline
- Start
- 2005-11
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |